Navigation Links
Cytochroma Closes $45 Million Series C Financing
Date:7/30/2008

p>Alan Lewis, Ph.D., Chairman of Cytochroma's Board of Directors, commented, "I would like to thank Elizabeth for her guidance in helping to bring Cytochroma to this important point in its development. I am also pleased to welcome Seiichi Kiso and Joe Regan to our Board and look forward to benefiting from their experience and expertise, as we continue to build a strong CKD-focused specialty pharmaceutical company."

Dr. Kiso joined Tanabe Seiyaku Co., Ltd. in 1982, where he served in managerial positions across Product Development, R&D Planning, and Corporate Development & Licensing. He has been General Manager, Business Development & Licensing Department, at MTPC since October 2007. Dr. Kiso received his MSc from Kyoto Pharmaceutical University, an MBA from Kobe University, and a PhD from Nagoya University School of Medicine.

Mr. Regan joined GrowthWorks in early 2003, and brings 15 years of life sciences venture capital and pharmaceutical industry experience. He has been active in both company creation and the strategic growth of portfolio companies. Mr. Regan has an Honours BSc from the University of Guelph and an MBA from McMaster University.

About Chronic Kidney Disease

According to the National Kidney Foundation, more than eight million patients in the U.S. suffer from moderate CKD (Stages 3 and 4) to severe CKD (Stage 5). Stages 3 and 4 CKD are characterized by progressively decreasing kidney function as measured by glomerular filtration rate. In Stage 5, kidney function is altogether absent and patients require regular dialysis or kidney transplant for survival. An estimated 70-90% of CKD patients have vitamin D insufficiency, which can lead to SHPT and resultant debilitating bone diseases. Mounting evidence continues to link vitamin D insufficiency with progression of CKD and death. CKD is caused most frequently by diabetes or hypertension, both of which are consequences of a growing obesity epidemic in countries worldwide.

'/>"/>
SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cytochroma Appoints R. Richard Wieland II As CFO
2. Cytochroma opens U.S. headquarters in Illinois
3. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
4. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
5. AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury
6. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
7. MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
8. Raptor Pharmaceuticals Closes $10 Million Private Placement
9. China Pharma Holdings, Inc. Closes $10 Million Financing
10. Transdel Pharmaceuticals Closes $4 Million Financing
11. Dilon Technologies Closes First Quarter With Record Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Bed bug cases tend to increase during summer. And ... risk of becoming the pests' next victim throughout the season, ... the guide, the company enumerated the steps of getting ... , According to My Cleaning Products, there are two ... during summer: the warm weather and the rise in travel. ...
(Date:5/24/2013)... 2013 The Oklahoma tornado left ... ravage, the mayor of Moore, one of the heavily damaged ... a report from cnn.com. Reaching out to also be of ... and Safe Shield to counter the looming mold problem. , ... May 22, 2013, caused 24 deaths, My Cleaning Products shared. ...
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
Breaking Biology Technology:Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... EDT , EAST BRUNSWICK, N.J., May 6 Savient Pharmaceuticals, ... the three months ended March 31, 2009. For the first ... million, or $0.41 per basic and diluted share, on total revenues ... or $0.33 per basic and diluted share on total revenues of ...
... Therapeutics (Nasdaq: NKTR ) today reported its financial ... loss for the quarter ended March 31, 2009 was $31.8 ... $40.7 million or $0.44 per share in the first quarter ... efficiencies as compared to a year ago. Total operating costs ...
... U.S. President Bill Clinton will,participate as one of the main ... 1 and 3 in Sao Paulo, Brazil. The event is ... of the most,important gatherings focused on biofuels in the world. ... Democratic president awarded a second term,in six decades. After leaving ...
Cached Biology Technology:Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 2Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 3Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 4Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 5Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 6Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 7Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 8Savient Pharmaceuticals Reports First Quarter 2009 Financial Results 9Nektar Therapeutics Reports First Quarter 2009 Financial Results 2Nektar Therapeutics Reports First Quarter 2009 Financial Results 3Nektar Therapeutics Reports First Quarter 2009 Financial Results 4Nektar Therapeutics Reports First Quarter 2009 Financial Results 5Nektar Therapeutics Reports First Quarter 2009 Financial Results 6Nektar Therapeutics Reports First Quarter 2009 Financial Results 7Nektar Therapeutics Reports First Quarter 2009 Financial Results 8Nektar Therapeutics Reports First Quarter 2009 Financial Results 9President Bill Clinton to Speak at the Ethanol Summit in Brazil 2
(Date:5/23/2013)... or harsh treatments because science fails to identify ... the disease. Researchers at Case Western Reserve University ... that allows patients to safely choose to do ... drastic measures. , The project is one of ... engineering at Case Western Reserve and director of ...
(Date:5/23/2013)... the team reveal the interplay of brain chemicals which ... Wellcome Trust and BBSRC. , By changing the ... perceptual abilities. While these changes can affect the strength ... fidelity of that response. , Lead author ... communicate with others, you can make yourself better heard ...
(Date:5/22/2013)... have developed a novel technique that can detect molecular ... that is one of the most important, though time-consuming, ... a paper in Nature , post-doctoral researcher David ... Schnell of the Center for Free-Electron Laser Science (CFEL) ... finely-tuned microwave fields to identify molecular variants apart, and ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Detecting mirror molecules 2Detecting mirror molecules 3
... discovered how the toxoplasmosis parasite may trigger the development ... from the University of Leeds, Faculty of Biological Sciences ... role in the development of these disorders by affecting ... messages in the brain controlling aspects of movement, cognition ...
... University Life Sciences researchers have discovered a new mechanism ... cells, which could lead to the development of a ... is transmitted to humans through bites from mosquitoes. According ... 350 million and 500 million cases of malaria occur ...
... Strosberg of Scripps Florida, was published on March 4, 2009, ... edition, Papers in Press. In the new study, ... more amino acids) derived from the core protein of hepatitis ... dimerization of the core protein (the joining of two identical ...
Cached Biology News:Research supports toxoplasmosis link to schizophrenia 2Researchers identify new way the malaria parasite and red blood cells interact 2Scripps research team identifies key molecules that inhibit viral production 2Scripps research team identifies key molecules that inhibit viral production 3
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... culture supernates and serum. Each kit contains ... fifteen 96-well plates, provided that the following ...
HIV-1 TAT (vN-21)...
Presenilin-1, N-terminus....
Biology Products: